Associated Papers
Targeting PCSK9 to tackle cardiovascular disease.
Hummelgaard S et al.
Pharmacology & Therapeutics, 2023
Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels.
Fruchart Gaillard C et al.
Molecular Metabolism, 2023
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.
Benjannet S et al.
The Journal of Biological Chemistry, 2012
Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease.
Gutiérrez-Cirlos C et al.
Annals of Hepatology, 0
[Familial homozygous hypercholesterolemia due to the c2271delT mutation in the LDL receptor gene, detected exclusively in Mexicans].
Martínez L et al.
Gaceta Medica De Mexico, 0
Select a paper to view details